In conclusion, sex and tumor location significantly influenced key molecular features such as PD-L1, MMR/MSI status and EGFR expression in CRC, suggesting that understanding sex differences together with tumor location may provide a clue to the possible development of future personalized therapeutic strategies in patients with CRC. This evidence concerns the gene EGFR and neoplasm.